Alternative to HRT for Menopausal Hot Flushes Now on NHS

Why It Matters

The approval expands treatment options for women who cannot use HRT, addressing a large unmet need and potentially reducing NHS costs associated with unmanaged menopause symptoms. It also signals broader acceptance of neuro‑targeted therapies in women's health.

Key Takeaways

• Veoza (fezolinetant) approved for NHS England.
• Non‑hormonal option for women unsuitable for HRT.
• Estimated 500,000 UK women could benefit.
• Not recommended for breast cancer or liver disease patients.
• Scotland's health board has not adopted Veoza yet.

Pulse Analysis

Menopause affects up to half of women in their 40s and 50s, with hot flushes and night sweats ranking among the most disruptive symptoms. For decades, hormone replacement therapy (HRT) has been the cornerstone of treatment, but contraindications such as deep‑vein thrombosis, cardiovascular disease, or personal preference leave a sizable cohort without safe options. Veoza, whose generic name is fezolinetant, works by antagonising neurokinin‑3 receptors in the hypothalamus, dampening the neural signals that provoke vasomotor episodes. Its daily oral formulation offers a practical alternative that does not involve estrogen. The drug’s safety profile has been confirmed in over 2,000 participants.

NICE’s endorsement of Veoza for the NHS was grounded in robust phase‑III trial data showing a statistically significant reduction in frequency and severity of vasomotor symptoms, alongside a favorable cost‑utility profile. The agency estimates that roughly 500,000 English women could be eligible, translating into potential savings from reduced GP visits, sleep‑related productivity loss, and secondary health complications. However, the guidance excludes patients with breast or other estrogen‑dependent cancers and those with liver disease, reflecting gaps in the clinical evidence base. Scotland’s health authority has so far declined to fund the drug, underscoring regional variability in adoption. Implementation will require clinician training to identify eligible patients and monitor outcomes.

The arrival of Veoza marks a watershed moment for non‑hormonal menopause therapeutics, signaling pharmaceutical confidence in neuro‑targeted pathways. Analysts predict a surge in R&D investment toward similar neurokinin‑3 antagonists and related agents, expanding the market beyond the traditional HRT segment. For healthcare providers, the drug adds a valuable tool to personalize menopause management, aligning with the NHS’s push toward patient‑centred care. As real‑world data accumulate, insurers and policymakers will likely reassess formulary decisions, potentially paving the way for broader European rollout. Long‑term pharmacovigilance will be essential to confirm its benefit‑risk balance across diverse populations.